RGNX (STOCKS)
REGENXBIO Inc.
$6.800000
+0.140000 (+2.10%)
Prev close: $6.660000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Curran M. Simpson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $351.54M
- Employees
- 353
- P/E (TTM)
- -1.19
- P/B (TTM)
- 16.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.72 | $-1.37 | -0.3543 | -25.94% |
|
Dec 2025 (Q4)
|
$-1.30 | $-0.98 | -0.3248 | -33.31% |
|
Sep 2025 (Q3)
|
$-1.20 | $-1.33 | +0.1316 | +9.88% |
|
Jun 2025 (Q2)
|
$-1.38 | $-1.12 | -0.2580 | -22.99% |
Financial Statements
| Revenues | $87.82M |
| Benefits Costs and Expenses | $360.71M |
| Costs And Expenses | $344.51M |
| Nonoperating Income/Loss | -$33.33M |
| Operating Expenses | $344.51M |
| Depreciation and Amortization | $15.52M |
| Research and Development | $232.55M |
| Other Operating Expenses | $104.23M |
| Operating Income/Loss | -$256.69M |
| Income/Loss From Continuing Operations After Tax | -$290.01M |
| Income/Loss From Continuing Operations Before Tax | -$272.89M |
| Net Income/Loss | -$290.01M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$290.01M |
| Net Income/Loss Available To Common Stockholders, Basic | -$290.01M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.60 |
| Diluted Earnings Per Share | -$5.60 |
| Basic Average Shares | 155,660,000 |
| Diluted Average Shares | 155,660,000 |
| Assets | $341.89M |
| Current Assets | $186.52M |
| Cash | $150.50M |
| Accounts Receivable | $10.04M |
| Prepaid Expenses | $11.54M |
| Other Current Assets | $14.44M |
| Noncurrent Assets | $155.38M |
| Fixed Assets | $101.87M |
| Other Non-current Assets | $53.50M |
| Liabilities | $320.81M |
| Current Liabilities | $71.11M |
| Accounts Payable | $21.21M |
| Wages | $9.37M |
| Other Current Liabilities | $40.54M |
| Noncurrent Liabilities | $249.70M |
| Equity | $21.08M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $21.08M |
| Liabilities And Equity | $341.89M |
| Net Cash Flow From Operating Activities | -$233.78M |
| Net Cash Flow From Operating Activities, Continuing | -$233.78M |
| Net Cash Flow From Investing Activities | $9.98M |
| Net Cash Flow From Investing Activities, Continuing | $9.98M |
| Net Cash Flow From Financing Activities | $108.93M |
| Net Cash Flow From Financing Activities, Continuing | $108.93M |
| Net Cash Flow | -$114.88M |
| Net Cash Flow, Continuing | -$114.88M |
| Comprehensive Income/Loss | -$290.12M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$290.12M |
| Other Comprehensive Income/Loss | -$108.00K |